On 11 April 2006, orphan designation (EU/3/06/364) was granted by the European Commission to Bayer HealthCare AG, Germany, for sorafenib tosylate for the treatment of hepatocellular carcinoma.
The sponsorship was transferred to Bayer Shering Pharma AG, Germany, in April 2009. Bayer Shering Pharma AG changed its name to Bayer Pharma AG in October 2011.
The sponsorship was transferred to Bayer AG, Germany, in August 2017.
Sorafenib tosylate for the treatment of papillary thyroid cancer has been authorised in the EU as Nexavar since 29 October 2007.
|Disease / condition||
Treatment of hepatocellular carcinoma
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.